Dr. Shah on Toxicites Associated With CAR T-Cell Therapy

Bijal D. Shah, MD
Published Online: Thursday, Nov 09, 2017



Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Although the toxicities associated with with CAR T-cell therapy receive a lot of attention, it remains the most promising therapy for relapsed leukemia, says Shah.

Shah adds that is important to understand that these toxicities are manageable, and the risk of dying from them is extremely low.
 


Bijal D. Shah, MD, medical oncologist, Moffitt Cancer Center, comments on the toxicities associated with using chimeric antigen receptor (CAR) T-cell therapy in patients with leukemia.

Although the toxicities associated with with CAR T-cell therapy receive a lot of attention, it remains the most promising therapy for relapsed leukemia, says Shah.

Shah adds that is important to understand that these toxicities are manageable, and the risk of dying from them is extremely low.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: The Emergence of CAR-T Cell Therapy for Hematologic Malignancies: Moving From Bench to BedsideDec 29, 20171.5
Cancer Summaries and Commentaries™: Update from San Diego—Advances in the Treatment of Myeloproliferative NeoplasmsDec 29, 20172.5
Publication Bottom Border
Border Publication
x